Call Us

ARTICLES

Arthrosamid®’s story started two decades ago. The brainchild of the team at Contura, the product had been in human use for various indications since 2000, and a favourable safety profile had already been established.

PATIENTS GAIN ACCESS TO INNOVATIVE NEW PROCEDURE FOR TREATING KNEE OSTEOARTHRITIS AS HCA UK PARTNERS WITH CONTURA ORTHOPAEDICS

London, September 2022; Contura Orthopaedics Ltd is pleased to announce that a major hospital group has signed up to Arthrosamid, allowing clinicians to offer this novel procedure to its patients in London and across the UK.

musculoskeletal disorders in addition to sporting injuries and complaints at its state-of-the-art facility located on Tottenham Court Road in Central London. The treatment will be rolled out across other facilities across the HCA Healthcare UK group in the coming months.

Arthrosamid is a polyacrylamide hydrogel first developed by Contura International Ltd. It is a long-lasting intra-articular injection approved in Europe for the treatment of knee OA. The treatment has the potential to change the present care pathway for managing OA, which affects approximately